PL3412672T3 - Postać krystaliczna A 2-butoksy-7-(4-(pirolidyn-1-ylometylo)benzylo)-5H-pirolo[3,2- d]pirymidyno-4-aminy jako agonisty TLR7, sposób wytwarzania i jej zastosowanie - Google Patents
Postać krystaliczna A 2-butoksy-7-(4-(pirolidyn-1-ylometylo)benzylo)-5H-pirolo[3,2- d]pirymidyno-4-aminy jako agonisty TLR7, sposób wytwarzania i jej zastosowanieInfo
- Publication number
- PL3412672T3 PL3412672T3 PL17747004T PL17747004T PL3412672T3 PL 3412672 T3 PL3412672 T3 PL 3412672T3 PL 17747004 T PL17747004 T PL 17747004T PL 17747004 T PL17747004 T PL 17747004T PL 3412672 T3 PL3412672 T3 PL 3412672T3
- Authority
- PL
- Poland
- Prior art keywords
- pyrrolo
- pyrrolidin
- pyrimidin
- ylmethyl
- butoxy
- Prior art date
Links
- VMDGIQUJSYPMLF-UHFFFAOYSA-N C(CCC)OC=1N=C(C2=C(N=1)C(=CN2)CC1=CC=C(C=C1)CN1CCCC1)N Chemical compound C(CCC)OC=1N=C(C2=C(N=1)C(=CN2)CC1=CC=C(C=C1)CN1CCCC1)N VMDGIQUJSYPMLF-UHFFFAOYSA-N 0.000 title 1
- 229940124615 TLR 7 agonist Drugs 0.000 title 1
- 239000013078 crystal Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610082029.8A CN107043379A (zh) | 2016-02-05 | 2016-02-05 | 一种tlr7激动剂的晶型a、其制备方法和医药用途 |
| EP17747004.4A EP3412672B1 (en) | 2016-02-05 | 2017-02-04 | Crystal form a of 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl) benzyl)-5h-pyrrolo[3,2-d]pyrimidin-4-amine as tlr7 agonist, preparation method and use thereof |
| PCT/CN2017/072891 WO2017133684A1 (zh) | 2016-02-05 | 2017-02-04 | 一种tlr7激动剂的晶型a、其制备方法和用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3412672T3 true PL3412672T3 (pl) | 2021-01-25 |
Family
ID=59499348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17747004T PL3412672T3 (pl) | 2016-02-05 | 2017-02-04 | Postać krystaliczna A 2-butoksy-7-(4-(pirolidyn-1-ylometylo)benzylo)-5H-pirolo[3,2- d]pirymidyno-4-aminy jako agonisty TLR7, sposób wytwarzania i jej zastosowanie |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US10442811B2 (https=) |
| EP (1) | EP3412672B1 (https=) |
| JP (1) | JP6889171B2 (https=) |
| KR (1) | KR102393280B1 (https=) |
| CN (2) | CN107043379A (https=) |
| AR (1) | AR107548A1 (https=) |
| AU (1) | AU2017215801B2 (https=) |
| CA (1) | CA3013518C (https=) |
| CL (1) | CL2018002092A1 (https=) |
| DK (1) | DK3412672T3 (https=) |
| EA (1) | EA035951B1 (https=) |
| ES (1) | ES2830443T3 (https=) |
| HR (1) | HRP20201644T1 (https=) |
| HU (1) | HUE051399T2 (https=) |
| IL (1) | IL260968B (https=) |
| LT (1) | LT3412672T (https=) |
| MX (1) | MX374297B (https=) |
| NZ (1) | NZ744884A (https=) |
| PH (1) | PH12018501643A1 (https=) |
| PL (1) | PL3412672T3 (https=) |
| PT (1) | PT3412672T (https=) |
| SG (1) | SG11201806683UA (https=) |
| SI (1) | SI3412672T1 (https=) |
| TW (1) | TWI754629B (https=) |
| UA (1) | UA121161C2 (https=) |
| WO (1) | WO2017133684A1 (https=) |
| ZA (1) | ZA201805186B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TN2018000112A1 (en) | 2015-10-29 | 2019-10-04 | Novartis Ag | Antibody conjugates comprising toll-like receptor agonist |
| CN107043379A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的晶型a、其制备方法和医药用途 |
| CN107043378A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体 |
| CN107043380A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途 |
| CN112105620B (zh) * | 2018-05-25 | 2026-02-24 | 正大天晴药业集团股份有限公司 | 用于治疗肺癌的tlr7激动剂及其药物组合 |
| JP7287708B2 (ja) | 2019-02-08 | 2023-06-06 | プロジェニア インコーポレイテッド | Ｔｏｌｌ－ｌｉｋｅ受容体７または８アゴニストとコレステロールの結合体およびその用途 |
| WO2020188448A1 (en) * | 2019-03-15 | 2020-09-24 | Janssen Sciences Ireland Unlimited Company | Toll-like receptor agonists for use in the treatment of hepatitis b |
| CN113543788B (zh) * | 2019-04-23 | 2023-12-19 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的固体药物组合物 |
| JP7811014B2 (ja) | 2020-03-02 | 2026-02-04 | プロジェニア インコーポレイテッド | 病原菌外壁成分基盤の生病原体模倣ナノ粒子及びその製造方法 |
| JP2023536954A (ja) | 2020-08-04 | 2023-08-30 | プロジェニア インコーポレイテッド | 活性化部位が一時的に不活性化したトール様受容体７または８作用薬と機能性薬物の結合体およびその用途 |
| US20230355750A1 (en) | 2020-08-04 | 2023-11-09 | Progeneer Inc. | Kinetically acting adjuvant ensemble |
| CN116322751A (zh) | 2020-08-04 | 2023-06-23 | 蛋白科技先锋 | 包含能够动力学控制的佐剂的mRNA疫苗 |
| CN119431359A (zh) * | 2023-07-28 | 2025-02-14 | 苏州申拓医药科技有限公司 | 一种tlr7/8激动剂的可药用盐、晶型及其制备方法、药物组合物和用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3376479B2 (ja) * | 1991-08-12 | 2003-02-10 | 武田薬品工業株式会社 | 縮合ピリミジン誘導体、その製造法および用途 |
| ES2577514T3 (es) * | 2005-08-22 | 2016-07-15 | The Regents Of The University Of California | Antagonistas de TLR |
| ES2467108T3 (es) | 2008-12-09 | 2014-06-11 | Gilead Sciences, Inc. | Moduladores de receptores tipo toll |
| EP2670244B1 (en) * | 2011-02-04 | 2018-04-11 | Duquesne University of The Holy Spirit | Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient |
| EP2800569B1 (en) * | 2012-01-05 | 2018-07-25 | Northeastern University | Allosteric modulators of cb1 cannabinoid receptors |
| LT2906563T (lt) * | 2012-10-10 | 2018-06-11 | Janssen Sciences Ireland Uc | Pirolo[3,2-d]pirimidino dariniai virusinių infekcijų ir kitų ligų gydymui |
| KR20150085081A (ko) * | 2012-11-20 | 2015-07-22 | 글락소스미스클라인 엘엘씨 | 신규 화합물 |
| MX358025B (es) * | 2012-11-20 | 2018-08-02 | Glaxosmithkline Llc Star | Compuestos novedosos. |
| US9550785B2 (en) | 2012-11-20 | 2017-01-24 | Glaxosmithkline Llc | Pyrrolopyrimidines as therapeutic agents for the treatment of diseases |
| JP6484253B2 (ja) * | 2014-05-01 | 2019-03-13 | ノバルティス アーゲー | Ｔｏｌｌ様受容体７アゴニストとしての化合物および組成物 |
| HUE054672T2 (hu) | 2014-08-15 | 2021-09-28 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | TLR7 agonistaként alkalmazott pirrolopirimidin vegyületek |
| CN105367576A (zh) | 2014-08-15 | 2016-03-02 | 正大天晴药业集团股份有限公司 | 作为tlr7激动剂的吡咯并嘧啶化合物 |
| CN107043380A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途 |
| CN107043379A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的晶型a、其制备方法和医药用途 |
-
2016
- 2016-02-05 CN CN201610082029.8A patent/CN107043379A/zh active Pending
-
2017
- 2017-02-03 TW TW106103695A patent/TWI754629B/zh active
- 2017-02-04 CN CN201780009747.5A patent/CN108602831B9/zh active Active
- 2017-02-04 HR HRP20201644TT patent/HRP20201644T1/hr unknown
- 2017-02-04 MX MX2018009501A patent/MX374297B/es active IP Right Grant
- 2017-02-04 UA UAA201809129A patent/UA121161C2/uk unknown
- 2017-02-04 KR KR1020187024627A patent/KR102393280B1/ko active Active
- 2017-02-04 US US16/075,297 patent/US10442811B2/en active Active
- 2017-02-04 HU HUE17747004A patent/HUE051399T2/hu unknown
- 2017-02-04 EA EA201891768A patent/EA035951B1/ru not_active IP Right Cessation
- 2017-02-04 SG SG11201806683UA patent/SG11201806683UA/en unknown
- 2017-02-04 CA CA3013518A patent/CA3013518C/en active Active
- 2017-02-04 PL PL17747004T patent/PL3412672T3/pl unknown
- 2017-02-04 PT PT177470044T patent/PT3412672T/pt unknown
- 2017-02-04 DK DK17747004.4T patent/DK3412672T3/da active
- 2017-02-04 LT LTEP17747004.4T patent/LT3412672T/lt unknown
- 2017-02-04 JP JP2018540799A patent/JP6889171B2/ja active Active
- 2017-02-04 ES ES17747004T patent/ES2830443T3/es active Active
- 2017-02-04 AU AU2017215801A patent/AU2017215801B2/en active Active
- 2017-02-04 WO PCT/CN2017/072891 patent/WO2017133684A1/zh not_active Ceased
- 2017-02-04 SI SI201730461T patent/SI3412672T1/sl unknown
- 2017-02-04 NZ NZ744884A patent/NZ744884A/en unknown
- 2017-02-04 EP EP17747004.4A patent/EP3412672B1/en active Active
- 2017-02-06 AR ARP170100297A patent/AR107548A1/es not_active Application Discontinuation
-
2018
- 2018-08-01 ZA ZA2018/05186A patent/ZA201805186B/en unknown
- 2018-08-02 PH PH12018501643A patent/PH12018501643A1/en unknown
- 2018-08-02 IL IL260968A patent/IL260968B/en unknown
- 2018-08-03 CL CL2018002092A patent/CL2018002092A1/es unknown
-
2019
- 2019-09-25 US US16/582,575 patent/US10947245B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3412672T3 (pl) | Postać krystaliczna A 2-butoksy-7-(4-(pirolidyn-1-ylometylo)benzylo)-5H-pirolo[3,2- d]pirymidyno-4-aminy jako agonisty TLR7, sposób wytwarzania i jej zastosowanie | |
| HUE061989T2 (hu) | Szubsztituált tieno[2,3-D]pirimidin származékok mint menin-MLL inhibitorai és alkalmazási eljárások | |
| IL247949A0 (en) | New histories of pyrazolopyrimidines and their use as malt1 inhibitors | |
| EP3096763A4 (en) | Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof | |
| PH12018501641B1 (en) | Tlr7 agonist trifluoroacetate salt and crystalline form b thereof, preparation methods and uses | |
| EP3115361A4 (en) | Heterocyclic compounds, and preparation method and use thereof | |
| IL253360A0 (en) | New crystalline forms of neratinib malate and a process for their preparation | |
| EP2978409A4 (en) | Ophthalmic composition, method for preparing the same, and use of the same | |
| IL260965B (en) | The malate salt as an agonist of tlr7, its c, d and e crystal structures, preparation methods and uses of the malate salt and the crystal structures | |
| IL260999B (en) | A method for the preparation of a pyrrolo[3,2-d] pyrimidine compound, and its intermediates | |
| EP3508481A4 (en) | CRYSTALLINE FORM OF OZANIMOD HYDROCHLORIDE AND PROCESS FOR PREPARING THE SAME | |
| EP3265455A4 (en) | CHEMICAL PROCESS FOR THE PREPARATION OF PYRIMIDINE DERIVATIVES AND INTERMEDIATE PRODUCTS THEREOF | |
| EP3188543A4 (en) | Configuration method, user equipment and base station of serving cell in dual connectivity | |
| EP3677575A4 (en) | CRYSTALLINE FORM OF OZANIMODHYDROCHLORIDE AND PRODUCTION METHOD THEREFOR | |
| EP3318639A4 (en) | Androgenetic haploid embryonic stem cell, and preparation method and use thereof | |
| EP3151933A4 (en) | Golf ball holder and method thereof | |
| EP3216791A4 (en) | Polymorphic substance of yonkenafil hydrochloride, preparation method therefor, and composition and use thereof | |
| EP3097099A4 (en) | An improved process for the preparation of trazodone and hydrochloride salt thereof | |
| GB2559718B (en) | Novel crystalline form of tribenuron-methyl, process for preparation and use thereof | |
| EP3177625A4 (en) | Amorphous form of 4-((4(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use | |
| EP3026049A4 (en) | Method for preparing benzamide derivative, novel intermediate used in preparation of benzamide, and method for preparing novel intermediate | |
| GB201720181D0 (en) | Process for preparing novel crystalline form of metsulfuron-methyl and use thereof | |
| UA107549C2 (uk) | ПОХІДНІ 4,7-ДИГІДРО-5-АМІНО-3-КАРБОКСАМІДО-6-ЦІАНО[1,2,3]ТРИАЗОЛО[1,5-а]ПІРИМІДИНУ І СПОСІБ ЇХ ОДЕРЖАННЯ |